Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The burden of faulty proofreading in colon cancer

A Corrigendum to this article was published on 26 September 2013

This article has been updated

Our understanding of inherited risk factors for colorectal cancer (CRC) is incomplete. A new study reports the identification of germline CRC risk variants that adversely affect the proofreading function of DNA polymerases encoded by POLE and POLD1.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Inherited DNA replication defects lead to CRC risk.

Change history

  • 05 September 2013

    In the version of the article initially published, reference 6 (J. Biol. Chem. 281, 4486–4494, 2006) should have been Genome 49, 403–410, 2006. Part of the associated sentence, "Alteration of this amino acid has been shown to lead to mutator phenotypes in yeast6," was revised to "Alteration of the equivalent residue in a related polymerase, POLD1, leads to mutator phenotypes in yeast6." In paragraph 4, alteration of a POLD1 residue in yeast, given as arginine, should have been asparagine. A sentence with an error in paragraph 7, "Similarly, tumors reported by Palles et al.4 that carried the POLE p.Leu424Val exonuclease-deficient germline variant also carried APC alterations," has been changed to state that the POLE p.Leu424Val variant alters an amino acid in the active site of the exonuclease domain. The revised sentence reads "Similarly, tumors reported by Palles et al.4 that carried the POLE p.Leu424Val germline variant, which maps to the active site of the exonuclease domain, also carried APC alterations." The legend for Figure 1 has been amended to include "Adapted with permission from ref. 5."


  1. Jemal, A. et al. CA Cancer J. Clin. 61, 69–90 (2011).

    Google Scholar 

  2. Fearon, E.R. Annu. Rev. Pathol. 6, 479–507 (2011).

    Article  CAS  Google Scholar 

  3. Burt, R. Drug Discov. Today Dis. Mech. 4, 293–300 (2007).

    Article  Google Scholar 

  4. Palles, C. et al. Nat. Genet. 45, 136–144 (2013).

    Article  CAS  Google Scholar 

  5. Preston, B.D., Albertson, T.M. & Herr, A.J. Semin. Cancer Biol. 20, 281–293 (2010).

    Article  CAS  Google Scholar 

  6. Murphy, K., Darmawan, H., Schultz, A., Fidalgo da Silva, E. & Reha-Krantz, L.J. Genome 49, 403–410 (2006).

    Article  CAS  Google Scholar 

  7. Albertson, T.M. et al. Proc. Natl. Acad. Sci. USA 106, 17101–17104 (2009).

    Article  CAS  Google Scholar 

  8. TCGA. Nature 487, 330–337 (2012).

  9. Seshagiri, S. et al. Nature 488, 660–664 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Somasekar Seshagiri.

Ethics declarations

Competing interests

The author is an employee of Genentech Inc. and holds Roche stocks.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Seshagiri, S. The burden of faulty proofreading in colon cancer. Nat Genet 45, 121–122 (2013).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer